india telmisartan market size, share & forecast 2026 | techsci research
DESCRIPTION
According to #TechSci Research report, the growing prevalence of hypertension is expected to drive the growth of India Telmisartan Market in the country. Report URL- https://bit.ly/3uGk4Ky Visit our website @ https://www.techsciresearch.com/ For more market research news visit our blog: https://techsciblog.com/TRANSCRIPT
MARKET INTELLIGENCE . CONSULTING
www.techsciresearch.com
INDIA TELMISARTAN MARKET
FORECAST & OPPORTUNITIES
FY2016 –FY2026
2
Scope of ReportProduct of Interest (POI): Telmisartan
Review Period
FY2016 – FY2019
Base Year
FY2020
Estimated Year
FY2021
Forecast Period
FY2022 – FY2026
Year Range
Telmisartan, sold under the brand name Micardis among others, is a medication used to treat high
blood pressure, heart failure, and diabetic kidney disease. It is a reasonable initial treatment for high
blood pressure.
Market Segmentation
COMPOSITION
• Single
• Combinational
REGION
• North
• South
• East
• West
• In-house
• Contract Manufacturing
Organizations
SOURCE
FORM
• Tablet
• Capsules
• Oral Solution
ROUTE OF
ADMINISTRATION
• Oral
• Intravenous
FORM
• Tablet
• Capsules
• Injection
• Others
DISTRIBUTION CHANNEL
• Online
• Offline
INDICATION
• Hypertension
• Cardiac Arrest
• Stroke
• Others
END USER
• Adult
• Pediatric
3© TechSci Research
Table of Contents
S. No. Contents Page No
1. Product Overview (Definition of product and major terminologies used in the report)
2.Research Methodology (Detailed description of the methodology used to conduct the research,Raw data backup, list of all secondary sources, List of respondents for primary surveys)
3. Impact of COVID-19 on India Telmisartan Market
4. Executive Summary
5. Manufacturing Telmisartan
5.1. Raw Material
5.2. Machinery
5.3. Manufacturing Methods
5.4. Contact Details of Machinery & Raw Material Supplies
6. Pharmacodynamic Overview of Telmisartan
6.1. Mechanism of Action
6.2. Absorption
6.3. Volume of Distribution
6.4. Protein Binding
6.5. Metabolism
6.6. Route of Elimination
6.7. Half-Life
6.8. Clearance
6.9. Toxicity
7. India Telmisartan Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
4© TechSci Research
Table of Contents
S. No. Contents Page No
7.2.1. By Source (In-house v/s Contract Manufacturing Organizations)
7.2.2. By Composition (Single, Combinational)
7.2.3. By Form (Tablet, Capsule, Injection, Others)
7.2.4. By Route of Administration (Oral v/s Intravenous)
7.2.5. By Distribution Channel (Online v/s Offline)
7.2.6. By Indication (Hypertension, Cardiac Arrest, Stroke, Others)
7.2.7. By End User (Adult v/s Pediatric)
7.2.8. By Region (North, East, West, South)
7.2.9. By Company (FY2020)
7.3. Product Market Map
8. Market Dynamics (This chapter assesses the major demand drivers and restraints.)
8.1. Drivers
8.2. Challenges
9.Market Trends and Developments (This section captures recent trends pertaining tomanufacturing or consumption, market movements in terms of points of production andconsumption, advancements and development)
10. Policy & Regulatory Landscape
10.1. Custom Duty & Taxes
10.2. Government Subsidy & Benefits
10.3. Relevant Policies & Regulations (GMP, USFDA, WHO Certifications)
11. Import & Export Analysis
12. Pricing Analysis
13. India Economic Profile
14. Competitive Landscape
5© TechSci Research
Table of Contents
S. No. Contents Page No
14.1. Competition Outlook
14.2. Company Profiles (Top 10 Leading Companies)
14.2.1. Company Details
14.2.2. Product Plants & Capacity
14.2.3. Financials (If Available)
14.2.4. Captive Consumption vs Merchant Sale
14.2.5. Current & Future Plans
15.Strategic Recommendations (Based on the findings of the report strategic recommendations onhow to enter and expand market share)
16. About Us & Disclaimer
RESEARCH METHODOLOGY
7
Research Methodology
✓ Identifying Key Opinion
Leaders
✓ Questionnaire Design
✓ In-depth Interviews
Data Collection
Developing List of Respondents
Formulating Questionnaire
Market Profiling
Data Validation
Data Analysis
In-depth secondary
research was conducted
to determine top
players in the India
telmisartan market,
overall market size and
segmental market size.
In order to conduct
industry experts’
interviews, TechSci
formulated a
detailed discussion
guide.
List of industry
players and
industry specialists
was developed.
TechSci conducted
interviews with
industry experts and
industry players for
data collection and
verification.
Data obtained as
a result of
primary and
secondary
research was
validated through
rigorous
triangulation.
The data was scrutinized
using MS-Excel,
statistical tools and
internal proprietary
database to obtain
qualitative and
quantitative insights
about the India
telmisartan market.
Data
Collection
Data Filter
& AnalysisResearch &
Intelligence
Actionable
InsightsBusiness
Solution
Primary Research Desk Research Company Analysis
✓ Recent Developments
✓ Market Changing
Aspects/Dynamics
✓ Government Policies
✓ Conclusion
✓ Market Participants
✓ Key Strengths
✓ TechSci Internal
Database
✓ Factiva
✓ Hoovers
Paid Sources
✓ Company Websites
✓ Company Annual
Reports
✓ White Paper Study
✓ Financial Reports
✓ Investor
Presentations
✓ Regulatory Body
✓ Associations, etc.
Secondary Research
Primary Research
8
Research Methodology
Baseline Methodology
Our dedicated team of industry experts has monitored and analyzed various aspects of India telmisartan market. The team has analyzed the outlook of
various segments of this market, while considering the major influencing factors such as surging population with cardiovascular and heart associated
disorders in India. The study includes market forecasting, which would enable our clients to take better decisions while planning their strategy to achieve
sustainability in India telmisartan market.
Methodology Followed for Calculation of Market Size:
• Market Size By Value & Volume : Market size, in terms of value, for the year FY2020 was calculated based on information collected through
exhaustive secondary research and primary surveys, with various key opinion leaders/stakeholders, such as manufacturers, suppliers, channel partners,
end users, industry experts, and other industry participants.
• The team interviewed more than 40 – 50 manufacturers, suppliers, 180 – 200 end users, and 15 – 20 industry experts and other value & volume chain
stakeholders in the India telmisartan market to obtain the overall market size from FY2016 to FY2020, which was validated by the Delphi technique.
Taking standard deviation into consideration, the market size was averaged out, to arrive at the market size data during FY2016-FY2020.
• Respondents were asked about the current and future market growth rates, market shares by source, by composition, by form, by route of
administration, by distribution channel, by indication, by end user, by region and by company. Removing the outlier responses, the geometric mean of
growth estimates and supplier wise revenue shares generated across various segments were considered, to arrive at the final revenue shares. Revenue
shares generated across various segments were further triangulated from other stakeholders.
9
Research Methodology
Methodology Followed for Calculation of Market Shares:
Market shares by source, by composition, by form, by route of administration, by distribution channel, by indication, by end user, by region and by
company were calculated based on the responses received through primary surveys with industry experts, in which the respondents were asked about
the market shares or revenue generated from various segments of telmisartan market. The final shares were calculated by taking the geometric mean
of the responses gathered from key opinion leaders after eliminating the outliers.
Methodology Followed for Forecasting:
• TechSci Research performed periodical checks on data collected through the surveys with logic checks and analyzed the survey results in
SPSS/Tableau Software.
• Data triangulation techniques were applied to fill the gaps and to present a more meaningful picture of the market. To forecast India telmisartan
market, TechSci Research used various forecast techniques such as:
✓ Moving Average
✓ Time Series Analysis
✓ Regression Analysis
✓ Econometric and Judgmental Analysis
10
Research Methodology
TechSci Research used its own forecast tool, which is based on the growth of various allied industries in respective regions. TechSci Research also used
the impact analysis during short, medium and long term period to estimate the demand and to reach accurate market numbers. It should be noted that
the figures compiled are only for the organized market including market share data.
Partial List of Companies Interviewed Key Secondary Sources
▪ Boehringer Ingelheim India Pvt. Ltd.
▪ Novartis India Ltd.
▪ Venus Remedies Ltd.
▪ Candomed Pharmaceuticals India Pvt. Ltd
▪ Torrent Pharmaceuticals Ltd.
▪ Cipla Limited (Exelan Pharmaceuticals)
▪ Astellas Pharma India Pvt. Ltd.
▪ Lupin Laboratories Ltd.
▪ 14.1.9. Mylan Laboratories Ltd.
▪ Glenmark Pharmaceuticals Ltd.
▪ World Bank
▪ TechSci Research Proprietary Database & Knowledge
Repository
▪ Company Annual Reports
▪ Industry Magazines
▪ Industry Reports
▪ News Dailies
▪ Credible Paid Databases
11
Industry Brief
According to TechSci Research report, “India Telmisartan Market By Indication (Hypertension, Cardiac Arrest, Stroke, Others), By Composition
(Single, Combinational), By Form (Tablet, Capsule, Injection, Others), By Route of Administration (Oral v/s Intravenous), By Source (In-house v/s
Contract Manufacturing Organizations), By Distribution Channel (Online v/s Offline), By End User (Adult v/s Paediatric), By Company, By Region,
Forecast & Opportunities, FY2026”, the India telmisartan market is expected to grow at a steady rate during the forecast period for the treatment
of essential hypertension. In addition to this, rising demand for developing antihypertensive drugs is expected to fuel the market growth through
FY2026. However, side-effects associated with drug consumption such as upper respiratory tract infections, diarrhea, back pain, kidney
problems, low blood pressure, and angioedema can restrict the market growth over the next few years. Moreover, in certain cases use of this
drug in pregnancy may harm the baby. This can further reduce the usage and application of the drug thereby hindering the market growth during
the forecast period.
The India telmisartan market is segmented based on indication, composition, form, route of administration, source, distribution channel, end user,
company, and region. Based on indication, the market can be fragmented into hypertension, cardiac arrest, stroke, others. The hypertension
segment is expected to dominate the market in the forthcoming years on account of rising prevalence of high blood pressure among the
population. Based on source, the market can be categorized into in-house v/s contract manufacturing organizations. The in-house segment
dominated the market until 2017 as most of the leading companies focus on in house production. Contract manufacturing organizations segment
is expected to witness significant growth in the market as it saves cost and maximize profits. Besides, high growth in number of contract
manufacturers is further contributing to its fast growing CAGR. In terms of form, the market is split into tablet, capsule, injection, others. Among
them, the capsule segment is anticipated to dominate the market in the next 5 years which is attributable to the fact that they are easy to use and
readily available. Also, the tablet segment is expected to register high growth during then forecast years on account of their properties such as
high stability of tablets and longer shelf life.
Astellas Pharma India Pvt. Ltd., Boehringer Ingelheim India Pvt. Ltd., Novartis India Ltd., Venus Remedies Ltd., Candomed Pharmaceuticals
India Pvt. Ltd, Torrent Pharmaceuticals Ltd., Cipla Limited (Exelan Pharmaceuticals), Lupin Laboratories Ltd., Mylan Laboratories Ltd., Glenmark
Pharmaceuticals Ltd., Astellas Pharma India Pvt. Ltd. and others are some of the leading players operating in India telmisartan market.
Companies operating in the market are using Go-To-Market strategies such as product launches, mergers, and collaborations to boost their
share and increase their geographic reach. For instance, In 2017, Zydus Cadila which is one of the leading pharmaceutical company in the
market received permission to sell its version of temisartan and hydrocholothiazide tablets and the drug was brought into the market in three
different dosages, which contributed in strengthening their market share.
“India Telmisartan market is expected to witness growth during the forecast period as it is used to treat patients with high blood pressure and
thereby aids to prevent strokes, heart attacks, and other related conditions in an individual. Telmisartan medication is also very effective in
treating diabetic kidney disease. This is further expected to create lucrative opportunities for the market growth of India Telmisartan market over
the next five years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based India management consulting firm.
12
Sample Data - Snapshot
5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
10.00 20.00 30.00 40.00 50.00 60.00 70.00 80.00 90.00 100.00 110.00
FY2016 FY2020 FY2021E FY2026F
By Value (USD Million)
By Volume (Million Units)
India Telmisartan Market Size, By Value (USD Million) & Volume (Million Units), FY2016–FY2026F
CAGR By Value & Volume
XX%
CAGR By Value & Volume
YY%
India Telmisartan Market Share, By Source, By Value, 2015–2025F
60%60%60%60%60%60%60%60%60%60%60%
40%40%40%40%40%40%40%40%40%40%40%
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021E
FY2022F
FY2023F
FY2024F
FY2025F
FY2026F
In-house Contract Manufacturing Organizations
India Telmisartan Market Share, By Indication, By Value, 2015–2025F
25%25%25%25%25%25%25%25%25%25%25%
25%25%25%25%25%25%25%25%25%25%25%
25%25%25%25%25%25%25%25%25%25%25%
25%25%25%25%25%25%25%25%25%25%25%
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021E
FY2022F
FY2023F
FY2024F
FY2025F
FY2026F
Hypertension Cardiac Arrest Stroke Others
13
Report Ordering
License Type Price
Electronic Access - Single User License $2950
Electronic Access - Multi-User License $3750
Custom Research License $7500
Report Price
To View Sample OR Purchase Report
Report Name: INDIA TELMISARTAN MARKET
FORECAST & OPPORTUNITIES
FY2016 –FY2026
About Us & Disclaimer
TechSci Research is a global market research and consulting company with offices in the US, UK and India. TechSci Research provides market research reports in number of areas
to organizations. The company uses innovative business models that focus on improving productivity, while ensuring creation of high-quality reports. The proprietary forecasting
models use various analyses of both industry-specific and macroeconomic variables on a state-by-state basis to produce a unique ‘bottom-up’ model of a country, regional and
global industry prospects. Combined with the detailed analysis of company activity and industry trends, the result is a uniquely rich evaluation of the opportunities available in the
market.
Related Reports
• India Streptomycin Market By Source (In-house v/s Contract Manufacturing Organizations), By Form (Tablet, Capsule and Injection), By Route of
Administration (Oral v/s Intravenous), By Type of Manufacturing Process (Natural, Synthetic and Semi-synthetic), By Distribution Channel (Online v/s
Offline), By Application (Tuberculosis, meningitis, throat Infection, endocarditis, brucellosis, plague, tularemia, rat bite fever and Others), By End User
(Adult v/s Paediatric), By Company, By Region, Forecast & Opportunities, FY2026
• India Potassium Clavulanate Market By Composition (Single, Combinational), By Route of Administration (Oral v/s Intravenous), By Form (Tablet,
Capsule, Syrup, Injection), By Distribution Channel (Online v/s Offline), By Source (In-house v/s Contract Manufacturing Organizations), By
Application (Respiratory Tract Infections, Skin Infections, UTI, Otitis media, Gynaecological infections, Bone and Joint Infections and Others), By End
User (Adult v/s Pediatric), By Company, By Region, Forecast & Opportunities, FY2026
The contents of this report are based on information generally available to the public from sources believed to be reliable. No representation is made that it is timely, accurate or
complete. TechSci Research has taken due care and caution in compilation of data as this has been obtained from various sources including which it considers reliable and first hand.
However, TechSci Research does not guarantee the accuracy, adequacy or completeness of any information and it is not responsible for any errors or omissions or for the results
obtained from the use of such information and especially states that it has no financial liability whatsoever to the subscribers / users of this report. The information herein, together
with all estimates and forecasts, can change without notice. All the figures provided in this document are indicative of relative market size and are strictly for client’s internal
consumption. Usage of the same for purpose other than internal will require prior approval of TechSci Research.
TechSci Research – North America708 Third Avenue, Manhattan,
New York, United States
Tel: +1- 646- 360- 1656
Email: [email protected]
www.techsciresearch.com
Disclaimer
TechSci Research – Europe54, Old brook, Bretton,
Peterborough,
United Kingdom
Email: [email protected]
www.techsciresearch.com
TechSci Research – Asia-PacificB – 44, Sector – 57, Noida, National Capital
Region, U.P. - India
Tel: +91-120-4523900
Email: [email protected]
www.techsciresearch.com